Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy is a research paper published in Cell (2017). On theSindex it has a DataRank of 12.7. It has been cited 5,568 times, with 200 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
1.3
From this paper's citation signal
Citation Network Contribution
11.4
From 200 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 200 citers.
NIH/NCI
Grant: R01 CA1633793
NIH/NCI
Grant: R35 CA197633
NIH/NCI
Grant: P01 CA168585
Cancer Prevention Research in Texas
Grant: RP120108
Cancer-Cancer Research Institute Cancer Immunology Dream Team Translational Research
Grant: SU2C-AACR-DT1012
NCATS NIH HHS
Grant: UL1 TR000124
NCI NIH HHS
Grant: K08 CA160692
NCATS NIH HHS
Grant: UL1 TR001881
NCI NIH HHS
Grant: R01 CA163793
National Institutes of Health
Grant: 1P01CA168585-01A1
TARGETED COMBINATORIAL TREATMENT OF BRAF MELANOMAS
National Institutes of Health
Grant: 2R35CA197633-08
Next Generation Cancer Immunotherapies to Defeat Melanoma
FWCI
157.28
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals